Charenton Le Pont

Researchers are observing the risk of malignancies and serious infections in patients with moderate to severe systemic lupus erythematosus SLE who receive anifrolumab compared with similar patients receiving standard care without anifrolumab. The study aims to gather real-world safety data on anifrolumab use in this population over an extended period. Participants who have been prescribed anifrolumab as part of their routine care are included, with the first anifrolumab prescription marking the start of observation. The study also follows a comparable group of moderate to severe SLE patients who do not initiate anifrolumab, comparing outcomes between these groups. No treatments are assigned by the study instead, data on serious infections and malignancies are collected up to November 2031. Throughout the study, participants health records are reviewed to monitor for malignancies, serious infections, infections leading to hospitalization, and infection-related deaths. The main outcomes are tracked from the index date first anifrolumab prescription or comparable date up to 2031 for malignancies and until 2027 for infections. This observational design allows for long-term safety assessment without altering participants usual care.

Researchers are evaluating the impact of a structured digital training program called Colo-ID on the accuracy of optical histology prediction for colorectal polyps detected during colonoscopy. The study focuses on improving the identification of polyp types using enhanced imaging, which may help optimize management strategies such as resect-and-discard for small polyps. This prospective, single-center observational study aims to assess how this training affects optical diagnosis performance in real-life clinical practice. Adults undergoing colonoscopy with at least one detected colorectal polyp will be included. During each procedure, endoscopists will record their optical prediction of the polyps histology. All polyps will be removed and sent for standard histopathological analysis. The digital training program involves a structured educational intervention to improve endoscopists skills in polyp characterization through image-based training and performance assessment. No patient management changes will occur due to the study. Participants will undergo routine colonoscopy with additional recording of optical diagnosis data before and after the training program. Researchers will compare optical prediction accuracy with histopathology results to measure concordance. Secondary assessments include diagnostic performance based on polyp size and location, inter-operator variability, and potential cost and environmental benefits. The study runs from February to June 2026 and maintains current patient care throughout.

Researchers are studying the use of computer-aided diagnosis CAD systems during colonoscopy to detect colorectal lesions and potentially reduce the risk of advanced adenomas or interval cancers over three years. The study addresses the challenge of missed lesions during colonoscopy and evaluates whether CAD can improve cancer prevention in patients undergoing colorectal cancer screening. Participants will be randomly assigned during their screening colonoscopy to receive either a standard colonoscopy or a colonoscopy assisted by a CAD system CAD EYE or GENIUS. After the initial procedure, patients will have a follow-up consultation one month later and then a scheduled colonoscopy at three years. For those at higher risk, the three-year follow-up colonoscopy will use the CAD system again, performed by a different investigator who is unaware of previous results. During the study, researchers will monitor outcomes such as the presence of advanced adenomas at 36 months, the number of adenomas detected, and the sensitivity and specificity of the CAD system. They will also evaluate the costs associated with CAD versus standard colonoscopy. Data from routine care colonoscopies will be collected for low-risk patients. The total participation duration extends to at least three years, including follow-up visits and repeat colonoscopies as scheduled.

The trial investigates the impact of different antibiotic treatments on the digestive tract colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae E-ESBL in children with febrile urinary tract infections UTIs. E-ESBL bacteria are a significant public health concern due to their resistance to many antibiotics. This research compares the emergence of E-ESBL strains in stools following treatment with either intravenous amikacin or other recommended antibiotics like ceftriaxone or cefixime in young children. Participants receive treatment for febrile UTIs with either amikacin given intravenously or with usual antibiotics such as intravenous or intramuscular ceftriaxone or oral cefixime. Before starting antibiotics, an anorectal swab is taken to check for E-ESBL colonization. A follow-up swab is performed three to four days after starting treatment to assess changes in bacterial presence. Children are monitored for the presence and type of E-ESBL bacteria in their stools four days after treatment begins. Researchers also track antibiotic resistance patterns, fever resolution, side effects related to antibiotic use, and the rate of UTI relapse over one and a half months. Participation involves stool sampling and clinical evaluations during the treatment period, with the study expected to complete by mid-2026.